One week ago, Neuralink’s video of its first female trial participant Audrey Crews creating art with neural control crossed two million views, generating most of the company’s recent press coverage. But the more strategically significant Neuralink news of the month came two weeks earlier and quieter. On 7 May 2026, Neuralink disclosed that the next-generation version of its R1 surgical robot can now place electrode threads into virtually any region of the human brain, including subcortical structures, opening Parkinson’s disease, refractory epilepsy, and treatment-resistant depression as new target indications beyond the motor-function restoration that current PRIME and CONVOY trial participants have demonstrated.
How the new R1 works
The R1 robot threads electrodes directly through the dura mater (the thick outermost membrane surrounding the brain) rather than removing it surgically, which lowers the trauma profile of the implantation procedure. A suite of eight optical coherence tomography (OCT) cameras and advanced scanners maps the brain tissue in real time, providing high-resolution visualisation beyond the superficial cortical layers and into subcortical regions. The robot also compensates in real time for the microscopic brain movement caused by heartbeat and respiration, which is the technical problem that has constrained reliable subcortical implantation across the broader brain-implant industry.
What the scope expansion enables
Neuralink’s current PRIME and CONVOY clinical trials have focused on motor-function restoration, with electrodes implanted in the motor cortex of participants with paralysis from spinal cord injury and ALS. The R1 capability expansion opens three new commercial indications that Neuralink has not previously addressed clinically.
Parkinson’s disease is the largest. The standard of care for medication-refractory Parkinson’s is deep brain stimulation (DBS) targeting the subthalamic nucleus or globus pallidus, dominated by Medtronic (Activa, BrainSense adaptive DBS), Abbott (Infinity), and Boston Scientific (Vercise). A Neuralink-class device reaching the same subcortical targets would enter a category with established reimbursement infrastructure and clinically validated stimulation parameters.
Refractory epilepsy is the second. NeuroPace’s RNS System (covered in Inside BCI’s 18 May piece on NeuroPace Q1 and NAUTILUS data) is the existing closed-loop standard, with focal-epilepsy approval and the IGE expansion currently in FDA review. A Neuralink architecture in this category would compete with RNS on hippocampal and thalamic targets.
Treatment-resistant depression is the third. Motif Neurotech (Inside BCI’s 27 April Motif IDE piece) recently received FDA Investigational Device Exemption for the DOT depression implant, and the MintNeuro-Motif silicon supply chain is now established. A Neuralink entry into the depression indication would compress the time the small clinical-stage players have to build commercial moat ahead of a top-three-funded competitor.
Why this matters now
The R1 scope expansion lands inside the same week as the NIH BRAIN Initiative’s 10-year Neuroscience Research Roadmap publication, which named four federally-funded Innovation Domains for the next decade of US neuroscience research. The federal roadmap explicitly stays inside the research-policy frame and does not name commercial-stage BCI companies. The Neuralink announcement is on the opposite track: a private-company commercial advance into the clinical indications federal research has long identified as the highest-value targets for neuromodulation. The two announcements together illustrate the structural split in US neurotechnology between federally-coordinated research priorities and privately-funded commercial execution.
The R1 capability expansion also extends Musk’s 1 January 2026 declaration that Neuralink’s defining goal for the year is industrial-scale implantation. Reaching any region of the brain is the engineering prerequisite for the broader patient population Musk has publicly targeted, beyond the paralysed-from-the-neck-down indication that the company built its early clinical evidence on.
What to watch
The first signal is the first Neuralink clinical trial in a non-motor-cortex indication. Neuralink has not yet disclosed a Parkinson’s, epilepsy, or depression trial filing, and the path from surgical-capability announcement to first-in-human in a new indication typically runs eighteen months to three years. The second signal is whether Neuralink discloses additional R1 technical specifications (channel counts, depth-of-reach, indication-specific stimulation parameters) at scientific conferences over the next two quarters. The third signal is the competitive response from Medtronic, Abbott, Boston Scientific, NeuroPace, and Motif Neurotech, all of whom now face a credible new entrant in indications they have been building independently for years.
Sources
- Neuralink Robot Reaches Any Brain Region (Tech Times, 20 May 2026)
- Neuralink’s next robot could reach any part of the brain (YourStory)
- Neuralink Develops Surgical Robot Capable of Reaching Any Brain Region (MEXC)
- Neuralink Surgical Robot: Precision AI For Next-Gen Brain Implants (Ubergizmo)
- Elon Musk’s Neuralink Scaling Plan (Neurofounders)
- Neuralink builds surgical robot to implant its brain chip in humans (E&T Magazine, 1 May 2026)
- Neuralink to Begin ‘High-Volume Production’ of Brain Chips in 2026, Musk Says (Fintool)